Asia/Oceania
I-Mab Begins Study of Uliledlimab Plus Tecentriq in Advanced Solid Tumors
The firm will evaluate the combination's efficacy and potential biomarkers of response in patients with ovarian cancer, head and neck cancer, NSCLC, TNBC, and other cancers.
OrigiMed, Janssen Partner to Improve Precision Cancer Medicine Development, Access in China
The companies will establish a real-world evidence database and use AI to identify new treatment indications and CDx development opportunities.
Hutchmed, AstraZeneca Begin Phase III Trial in NSCLC With EGFR, MET Mutations
The trial will evaluate Orpathys plus Tagrisso in patients with advanced or metastatic EGFR-positive, MET-amplified NSCLC who have progressed after EGFR inhibitor therapy.
HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders
Premium
New data from a Japanese Phase II study have solidified a path forward for pertuzumab plus trastuzumab in HER2-positive colorectal cancer patients.
Jiangsu Hengrui Licenses CStone Pharmaceuticals' Anti-CTLA-4 Candidate in Greater China
The drug, CS1002, is being studied in melanoma, hepatocellular carcinoma, and microsatellite instability high or mismatch repair deficient tumors.